| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PS-47's primary target is PDK1, but it shows very low binding affinity (Kd > 200 µM), making it effectively inactive. It is the inactive E-isomer of PS48. The compound is also described as targeting the p47phox subunit of NADPH oxidase, an enzyme complex involved in the generation of reactive oxygen species. However, its primary application is as a negative control for PS48 in PDK1 studies.
|
|---|---|
| ln Vitro |
PS47 has extremely little affinity (Kd>200 µM) for PDK1 [1].
In vitro, PS-47 shows very low binding affinity or no binding to PDK1 (Kd > 200 µM), making it an inactive control. It does not activate PDK1, unlike its active isomer PS48. The compound is used as a negative control in PDK1 activity assays to distinguish specific effects of PS48 from non-specific effects. Its inactivity confirms the specificity of PS48's effects on PDK1. |
| ln Vivo |
In vivo, PS-47 is not used as a therapeutic agent. It is used as a negative control in research studies to validate the specificity of PS48's effects. Its inactivity ensures that any observed effects of PS48 are due to its activity on PDK1 and not to non-specific effects of the compound scaffold. The compound is not intended for therapeutic use and is used exclusively in research settings.
|
| Enzyme Assay |
The in vitro activity of PS-47 is assessed using cell-free kinase assays similar to those used for PS48. Recombinant PDK1 is incubated with a substrate peptide and ATP in the presence of varying concentrations of PS-47. The phosphorylation of the substrate is measured using a radioactive or fluorescence-based method. The lack of activity (Kd > 200 µM) confirms that PS-47 does not bind to or activate PDK1. Binding affinity can also be assessed using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC).
|
| Cell Assay |
For cellular assays, PS-47 is used as a negative control alongside PS48. Cells are treated with PS-47 at concentrations comparable to those used for PS48 (typically 1-100 µM) for defined periods. The phosphorylation of PDK1 substrates (e.g., Akt at Ser473) is analyzed by Western blotting. The lack of effect on PDK1 substrate phosphorylation confirms that PS-47 is inactive and serves as a valid negative control. Cell viability and other cellular parameters can also be assessed to ensure that any effects of PS48 are specific.
|
| Animal Protocol |
In vivo, PS-47 is not typically administered to animal models. It may be used in control groups in studies where PS48 is being tested. The compound would be administered via the same route and at similar doses as PS48 to ensure that any observed effects are specific to PS48's activity. However, specific in vivo protocols for PS-47 are not detailed in the provided search results.
|
| ADME/Pharmacokinetics |
PS-47 has a molecular weight of 286.75 g/mol and a molecular formula of C17H15ClO2. It is soluble in DMSO. The compound should be stored under appropriate conditions to maintain stability. Its chemical properties are similar to those of PS48, differing only in the configuration of the double bond (E-isomer vs. Z-isomer).
|
| Toxicity/Toxicokinetics |
Specific toxicity data for PS-47 is not available in the provided search results. As an inactive compound with very low binding affinity to PDK1, it is not expected to have significant biological activity or toxicity. However, standard laboratory safety precautions should be followed when handling the compound. Its use as a negative control in research studies does not require extensive toxicological characterization.
|
| References | |
| Additional Infomation |
PS-47 is a research compound used as a negative control for PS48 in studies of PDK1 signaling. PS48 is a potent activator of PDK1 that binds to the PIF-binding pocket. PS-47, being the inactive E-isomer, does not bind to PDK1 and is used to confirm the specificity of PS48's effects. The compound is also described as a selective small-molecule inhibitor targeting the p47phox subunit of NADPH oxidase. However, its primary application in research is as a negative control. PS-47 is not approved for clinical use and is intended for research purposes only. It is available from chemical suppliers for research applications.
|
| Molecular Formula |
C17H15CLO2
|
|---|---|
| Molecular Weight |
286.75
|
| Exact Mass |
286.076
|
| CAS # |
1180676-33-8
|
| PubChem CID |
44141942
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
337
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)/C(=C/C(=O)O)/CCC2=CC=C(C=C2)Cl
|
| InChi Key |
LLJYFDRQFPQGNY-NTCAYCPXSA-N
|
| InChi Code |
InChI=1S/C17H15ClO2/c18-16-10-7-13(8-11-16)6-9-15(12-17(19)20)14-4-2-1-3-5-14/h1-5,7-8,10-12H,6,9H2,(H,19,20)/b15-12+
|
| Chemical Name |
(E)-5-(4-chlorophenyl)-3-phenylpent-2-enoic acid
|
| Synonyms |
PS47; PS 47; PS-47
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~348.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.72 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4874 mL | 17.4368 mL | 34.8736 mL | |
| 5 mM | 0.6975 mL | 3.4874 mL | 6.9747 mL | |
| 10 mM | 0.3487 mL | 1.7437 mL | 3.4874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
